Strategy At Novartis: Culture Change As The 'How' Behind The 'What'
• By William Looney
If strategic planning is a necessary hedge against the drawn-out, asset-draining product cycles of today’s big pharma enterprise, then what is the secret of doing it well? In Vivo looks for answers in a conversation with Novartis strategy lead Stephen Moran.
Stephen Moran, Global Head of Strategy for Novartis • Source: Novartis AG
This article is part of the Outlook 2019 series – an annual collection provided exclusively to subscribers of Informa Pharma Intelligence publications.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.
MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.